The Mito-Peptide Advanced Protocol
A mitochondrial signalling protocol built around the mitochondrial-derived peptides humanin and MOTS-c — and honest about where their evidence stops. Layer 0 is the intervention shown to raise both peptides in humans: high-intensity exercise. Layer 1 is cofactors with human trials, CoQ10 and optional PQQ. Layer 2 is MOTS-c as an optional, clearly labelled experimental layer with no human trial behind its dose. Humanin is a research tier with no dose at all, and SLU-PP-332 is a watch-list compound that is deliberately not a step. Graded D to its weakest layer.
Daily Schedule
Timing and dosage for each step
Layer 1 — morning with a fat-containing meal, from week 0
200 mg
200 mg/day ubiquinone or ubiquinol with fat. The only layer with human outcome trials: a meta-analysis of 13 RCTs (1,126 participants) found reduced fatigue scores versus placebo (Hedges' g −0.398), with larger effects at higher dose and longer duration, and one adverse event among 602 treated. Q-SYMBIO in heart failure used 100 mg three times daily for two years. This layer runs regardless of everything below it.
Layer 1 — morning, from week 0
20 mg
20 mg/day. In a six-week RCT in untrained men following supervised endurance training, PQQ raised PGC-1α protein versus placebo but did NOT improve aerobic performance or body composition. Read it as a biogenesis-marker result, not a performance result. Optional: drop it without regret if the budget is tight.
Layer 2 — OPTIONAL experimental layer, subcutaneous, training days, weeks 5–10 only
10 mg
⚠️ Research peptide with NO published human administration trial. The 10 mg figure is the community convention from this site's MOTS-c profile, not a trial dose — all dosing evidence is from mice. Animal data: prevented diet-induced obesity and insulin resistance, and improved physical performance in young, middle-aged and old mice. ⚠️ AMPK activator: additive glucose lowering with metformin, berberine or insulin. ⚠️ Prohibited class for tested athletes. Skip this layer entirely and the protocol still stands.
Read This Before the Protocol
The only intervention on this page proven to raise mitochondrial-derived peptides in humans is exercise. A 2021 review of the human studies concluded that acute high-intensity exercise can increase humanin and MOTS-c in skeletal muscle and plasma. A 2021 Nature Communications paper reported that exercise induces endogenous MOTS-c in human muscle and circulation. No trial has shown the same of an injected peptide in a person, because no such trial has been published.
That fact sets the order of this protocol. Exercise is Layer 0 and it is not optional. Cofactors with human trials are Layer 1. The peptide the protocol is named after is Layer 2, optional, and labelled as an experiment.
Three groups should read the safety section first. Anyone with a current or previous cancer — humanin works by blocking apoptosis, and MOTS-c's effect on tumours in humans is unstudied. Anyone on glucose-lowering medication — MOTS-c is an AMPK activator. And tested athletes — AMPK activators and unapproved substances are prohibited.
How This Differs From the Mitochondrial Matrix
This site already has The Ultimate Mitochondrial Matrix. The two are alternative routes, not stages of one plan.
| Mitochondrial Matrix | Mito-Peptide Advanced | |
|---|---|---|
| Central idea | Repair the organelle | Work with the organelle's signals |
| Lead compound | SS-31 (inner membrane, cardiolipin) | Exercise, then MOTS-c |
| NAD+ layer | NMN | None |
| Built for | Fatigue and age-related energy decline | Exercise response and metabolic signalling |
| Starts with | An injection | A training plan |
If your problem is fatigue at rest, the Matrix is the closer fit. If you already train and want to know whether the peptide layer adds anything, this is the protocol — and its honest answer is "unproven."
The Layer Logic
| Layer | What | Evidence grade | Optional? |
|---|---|---|---|
| 0 — Exercise | High-intensity intervals plus aerobic base | B for raising the peptides acutely | No |
| 1 — CoQ10 | Electron-transport cofactor | B (fatigue meta-analysis, heart-failure RCT) | No |
| 1 — PQQ | Biogenesis marker support | C (PGC-1α up, performance unchanged) | Yes |
| 2 — MOTS-c | The mitochondrial-derived peptide | D (animal only) | Yes — experimental |
| Research tier — Humanin | Follow the literature | D | No dose exists |
| Watch list — SLU-PP-332 | Not a step | D | Not included |
The protocol is graded D — to its weakest layer, which is the layer it is named after. Layers 0 and 1 alone would be a B. The reasoning is set out at length in The Advanced Mitochondrial Stack.
Layer 0 — Exercise
Two to three high-intensity interval sessions a week on top of an aerobic base. This is the stimulus that raised humanin and MOTS-c in the human studies, and it is the stimulus that activates the ERR and PGC-1α programmes the experimental compounds are trying to imitate.
One caveat keeps this honest. The acute rise after a hard session is established; whether training produces a lasting change in resting peptide levels is conflicting across studies, and appears to depend on training mode, intensity and who is being trained. And a 2026 study found no arterio-venous difference in MOTS-c across the working leg during exercise — suggesting skeletal muscle may not be the source of the circulating peptide at all. The biology is still being mapped.
Layer 1 — Cofactors With Human Trials
CoQ10, 200 mg/day with fat. Thirteen randomised trials in 1,126 people found lower fatigue scores than placebo, with the effect growing with dose and duration and a single adverse event among 602 treated participants. In chronic heart failure, the two-year Q-SYMBIO trial cut major adverse cardiovascular events from 26% to 15%. This is the load-bearing supplement layer.
PQQ, 20 mg/day — optional. The honest reading of the best trial: 23 untrained men, six weeks of supervised endurance training, PQQ versus placebo. PGC-1α protein rose more on PQQ. Aerobic performance did not differ between groups. A marker moved; an outcome did not.
Layer 2 — MOTS-c, Labelled Honestly
MOTS-c is a 16-amino-acid peptide encoded in the mitochondrial 12S rRNA gene. In mice it prevented age-dependent and diet-induced insulin resistance, and improved physical performance at 2, 12 and 22 months of age; late-life intermittent treatment three times a week increased physical capacity and healthspan.
In humans it has no published administration trial. The dose in this protocol is a convention, not a finding. If you take this layer:
- Run it for six weeks, not continuously, on training days.
- Start it only after four weeks of Layers 0 and 1, so you have a baseline to compare against.
- Stop at any hypoglycaemic symptom.
- Accept that an improvement over those six weeks cannot be attributed to the peptide rather than the training.
Skipping this layer costs you nothing that has been demonstrated in a person.
Research Tier — Humanin, No Dose
Humanin is the founding member of the class. Its levels fall with age and run higher in the children of centenarians, and its analogue HNG improved metabolic markers in middle-aged mice. It has never been given to humans in a published trial, so this protocol assigns it no step and no dose. Its role here is a reading list.
Watch List — SLU-PP-332, Not a Step
SLU-PP-332 is a small-molecule ERR agonist — not a peptide — with strong mouse data and no human data. Its developers report that it lacks oral bioavailability. It is excluded from this protocol on purpose; the case is made in the research update.
When to Stop and See a Clinician
- Fatigue at rest that is new or worsening. That is a symptom to investigate — thyroid, anaemia, sleep apnoea, depression, cardiac causes — before it is a stack to build.
- Any hypoglycaemic episode on the MOTS-c layer, especially alongside metformin, berberine or insulin.
- A cancer diagnosis, current or past. Do not take the peptide layers without an oncologist's view.
- Chest pain, breathlessness or palpitations during interval training. Stop the session and get assessed before resuming.
- You are a tested athlete. Layers 0 and 1 only.
Monitoring
| Marker | When | Why |
|---|---|---|
| VO2max or a fixed time trial | Baseline, week 4, week 10 | The functional output; week 4 isolates Layers 0–1 from Layer 2 |
| Fasting glucose and insulin (HOMA-IR) | Baseline, week 10 | MOTS-c's claimed effect is insulin sensitivity |
| Home fasting glucose | Weekly during Layer 2 | Catches additive glucose lowering |
| Resting heart rate and HRV | Weekly | Training load, not peptide effect |
| Fatigue score on a fixed scale | Weekly | The CoQ10 trials measured exactly this |
Safety and Scope
MOTS-c and humanin are research peptides with no approved human use; SLU-PP-332 is a research chemical. CoQ10 and PQQ are supplements. Nothing here treats mitochondrial disease, chronic fatigue syndrome or diabetes. Pregnant and breastfeeding women should use Layer 0 as their clinician advises and nothing else on this page.